REV-ERB comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
== Kaposi's sarcoma (176–176) == 176 Kaposi's sarcoma 176.0 Kaposi's sarcoma skin 176.1 Kaposi's sarcoma soft tissue 176.2 Kaposi's sarcoma palate 176.3 Kaposi's sarcoma gastrointestinal sites 176.4 Kaposi's sarcoma 176.5 Kaposi's sarcoma lymph nodes 176.8 Kaposi's sarcoma other specified sites 176.9 Kaposi's sarcoma unspecified site
== Diagnosis == The clinical diagnosis of BPD can be made through a psychiatric assessment conducted by a mental health professional, ideally a psychiatrist or psychologist. This comprehensive assessment integrates various sources of information to confirm the diagnosis, encompassing the patient's self-reported clinical history, observations made by the clinician during interviews, and corroborative details obtained from family members, friends, and medical records. Patients should be thoroughly assessed for co-morbid mental health conditions, substance use disorders, suicidal ideation, and any self-harming behaviors. An effective approach involves presenting the criteria of the disorder to the individual and inquiring if they perceive these criteria as reflective of their experiences. Involving individuals in the diagnostic process may enhance their acceptance of the diagnosis. Despite the stigma associated with BPD and previous notions of its untreatability, disclosing the diagnosis to individuals is generally beneficial. It provides them with validation and directs them to appropriate treatment options. The psychological evaluation for BPD typically explores the onset and intensity of symptoms and their impact on the individual's quality of life. Critical areas of focus include suicidal thoughts, self-harm behaviors, and any thoughts of harming others. The diagnosis relies on both the individual's self-reported symptoms and the clinician's observations.
Cement manufacture causes environmental impacts at all stages of the process. These include emissions of airborne pollution in the form of dust, gases, noise and vibration when operating machinery and during blasting in quarries, and damage to countryside from quarrying. Equipment to reduce dust emissions during quarrying and manufacture of cement is widely used, and equipment to trap and separate exhaust gases are coming into increased use. Environmental protection also includes the re-integration of quarries into the countryside after they have been closed down by returning them to nature or re-cultivating them.
In this role, she serves as an advocate and liaison for basic science researchers working in clinical departments to help facilitate the combination of “basic research” which seeks to answer fundamental scientific questions and “translational research” that seeks to put those findings to use, for example in a clinical setting. In 2020, she was named director of the department of pharmacology and molecular sciences at Johns Hopkins University School of Medicine, becoming the first African-American director of a basic science department, and the first Black woman to chair any department, at Johns Hopkins University School of Medicine. Outside of Johns Hopkins, Bumpus chaired the National Institute of Health (NIH)'s Xenobiotic and Nutrient Disposition and Action study section and served as a science commissioner and member of Washington, D.C.’s Science Advisory Board. She was an associate editor of the journal Drug Metabolism and Disposition. She has been strongly involved with the American Society for Pharmacology and Experimental Therapeutics (ASPET), where she served as secretary and treasurer and president.
Sources: en.wikipedia.org
Southeast of the city centre stands San Salvario district, which extends from Corso Vittorio Emanuele II to Corso Bramante and is delimited by the Turin-Genoa railway on the west side and by the River Po on the east side. Home to an increasing immigrants' community, the district is an example of integration among different cultures; it also features an incremented nightlife after the opening of several low-cost bars and restaurants. San Salvario is crossed by two main roads, Via Nizza and Via Madama Cristina, and just as the city centre it is characterised by the grid plan typical of Turin's old neighbourhoods. The hub of the district is Piazza Madama Cristina which hosts a big open market, while several commercial activities flourish around it. The celebrated Parco del Valentino is situated in the east side of San Salvario and, albeit not in downtown, it represents a type of central park of Turin. Thanks to the vicinity to the city centre, the park is very popular among the local people, during the day but also at night, because of the several bars and nightclubs placed here. From the terraces of Parco del Valentino, many sights of the hills on the other side of the river can be appreciated. In the centre of the park stands the Castello del Valentino, built in the 17th century. This castle has a horseshoe shape, with four rectangular towers, one at each angle, and a wide inner court with a marble pavement. The ceilings of the false upper floors are in transalpino (i.e. French) style. The façade sports the huge coat of arms of the House of Savoy.
=== 11 December === Ukrainian President Volodymyr Zelenskyy said that Russian forces have turned the city of Bakhmut into "burned ruins". The Ukrainians killed up to 60 and injured nearly 100 Russian soldiers near Kadiivka, Luhansk Oblast. They also killed 150 Russian soldiers and destroyed 10 pieces of equipment during strikes in Zaporizhzhia Oblast.
Decomposition and pressure buildup — The confinement or unintended heating of concentrated solutions can result in rapid gas evolution, leading to the risk of vessel rupture. Incompatibilities and catalysis by transition metals or organics — The presence of trace contaminants, metal ions, or organic reducing agents may accelerate decomposition or trigger radical pathways. Thermal runaway or self-accelerating decomposition — In the context of peroxide chemistry, it is crucial to consider the self-accelerating decomposition temperature (SADT) and to avoid scaling up reactions without conducting a thorough hazard assessment. Oxidizer hazards in the presence of organics — Hydrogen peroxide acts as an aggressive oxidizer. When in contact with organic substrates, solvents, or flammable materials, the risk of fire or explosion is heightened; therefore, it is essential to ensure that oxidizer storage is kept separate from reducing materials. High-concentration hydrogen peroxide streams, typically above 40%, should be considered hazardous due to concentrated hydrogen peroxide's meeting the definition of a DOT oxidizer according to U.S. regulations if released into the environment. The EPA Reportable Quantity (RQ) for D001 hazardous wastes is 100 pounds (45 kg), or approximately 10 US gallons (38 L), of concentrated hydrogen peroxide.
== Taste == Because the ground coffee beans in cold-brewed coffee never come into contact with heated water, the process of leaching flavor from the beans produces a chemical profile different from conventional brewing methods. Coffee beans contain a number of compounds that are more soluble at higher temperatures, such as caffeine, oils and fatty acids. However, brewing at a lower temperature for 24 hours results in higher caffeine content when brewed in equal volume compared to 6 minutes at 98 °C (208 °F). The acidity of cold and hot brew coffee is similar but cold brew coffee has a lower titratable acid concentration. Both pH and titratable acidity influence taste.
=== Electrical conductivity and electrolysis === Pure water has a low electrical conductivity, which increases with the dissolution of a small amount of ionic material such as common salt. Liquid water can be split into the elements hydrogen and oxygen by passing an electric current through it—a process called electrolysis. The decomposition requires more energy input than the heat released by the inverse process (285.8 kJ/mol, or 15.9 MJ/kg).
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.